Breast Cancer
Conference Coverage
TAILORx: Clinical data add value to recurrence score
CHICAGO – Clinical risk stratification adds prognostic value to the 21-gene recurrence score for guiding treatment selection in patients with...
News
FDA approves trastuzumab-anns for HER2-positive breast, gastric cancer
This is the fifth FDA approval of a trastuzumab biosimilar.
Conference Coverage
Breast cancer linked to 23% higher risk for new diabetes
It’s a “clear signal” of extra risk, researcher says, but there’s no explanation yet.
Conference Coverage
PREDIX HER2 trial: Similar efficacy, less toxicity with T-DM1 for HER2+, HR+ breast cancer
T-DM1 had similar efficacy and less toxicity vs. standard chemotherapy for patients with HER2- and HR-positive breast cancers in the phase 2...
Conference Coverage
KRISTINE: Three-year data help forge path to T-DM1-based deescalation in HER2+ BC
CHICAGO – T-DM1 plus pertuzumab reduced toxicity in patients with HER2-positive stage I-III breast cancer in the KRISTINE study, but led to lower...
Conference Coverage
Pregnancy deemed safe in BRCA-mutated breast cancer survivors
Pregnancy did not affect disease-free or overall survival, and complications were similar to the general population.
Article
2019 Update on menopause
What is the risk of endometrial cancer in women with postmenopausal bleeding, and who should be evaluated? Plus, consensus...
News
ASCO clinical practice guideline update incorporates Oncotype DX
In women with hormone receptor–positive, axillary node–negative breast cancer with Oncotype DX recurrence scores of less than 26, there is minimal...
Article
What to do when a patient presents with breast pain
Most breast pain is due to hormonal and fibrocystic changes, with conservative measures and patient reassurance prioritized. Here, types of breast...
Conference Coverage
Ribociclib/ET improves OS in premenopausal women with HR+/HER2- breast cancer
CHICAGO – Adding ribociclib to an aromatase inhibitor or tamoxifen was associated with an 29% relative reduction in...